Presentation is loading. Please wait.

Presentation is loading. Please wait.

PK/PD - ICC - Manila, June 5th, 20051 The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul.

Published byZoe Parrish Modified over 9 years ago

Similar presentations

Presentation on theme: "PK/PD - ICC - Manila, June 5th, 20051 The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul."— Presentation transcript:

1 PK/PD - ICC - Manila, June 5th, 20051 The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels, Belgium Founding member and past-president (1998-2000) of ISAP www.facm.ucl.ac.bewww.isap.org

2 PK/PD - ICC - Manila, June 5th, 20052 The situation in the early 90's … anti-infective drug doising was largely irrational or not based on sounds pharmacodynamics / toxicodynamics search for low doses for fear of toxicity “errors” in drug dosages at registration misunderstanding of what is an optimal schedule and what it implies pharmacokinetics was mainly used to establish “drug presence” rather than to make true correlations with efficacy

3 PK/PD - ICC - Manila, June 5th, 20053 PK/PD of antiinfectives : what has been done ? Over the last 10 years, three major concepts have emerged and proven useful : dose-effect relationships are not the same for all anti-infectives beta-lactams vs. fluoroquinolones or aminoglycosides integration of PK/PD within pre-clinical and early clinical development allows prediction of success or failure of new antimicrobials PK/PD may help in preventing the emergence of resistance

4 PK/PD - ICC - Manila, June 5th, 20054 PK /PD in action in the Regulatory in the USA FDA July 1998 http://www.fda.gov/cder/present/anti-infective798/biopharm/index.htm

5 PK/PD - ICC - Manila, June 5th, 20055 PK /PD in action in the Regulatory in the USA http://www.fda.gov/cder/present/anti-infective798/biopharm/index.htm FDA November 2002

6 PK/PD - ICC - Manila, June 5th, 20056 PK /PD in action in the Regulatory in Europe " Inadequate dosing of antibiotics is probably an important reason for misuse and subsequent risk of resistance. A recommendation on proper dosing regimens for different infections would be an important part of a comprehensive strategy. The possibility of approving a dose recommendation based on pharmacokinetic and pharmacodynamic considerations will be further investigated in one of the CPMP* working parties… " * Committee for Proprietary Medicinal Products EMEA July 1999

7 PK/PD - ICC - Manila, June 5th, 20057 Publications of the EMEA...

8 PK/PD - ICC - Manila, June 5th, 20058 The basis of PK/PD Dosage regimen Concentration versus time in serum Concentration versus time in tissues and other body fluids Concentration versus time at site of infection Pharmacologic or toxicologic effect Antimicrobial effect versus time absorption distribution elimination PHARMACOKINETICSPHARMACODYNAMICS Craig (1998) CID 26:1-10

9 PK/PD - ICC - Manila, June 5th, 20059 Moving from PK to PD … Pharmacokinetics conc. vs time Conc. Time 025 0.0 0.4 PK/PD effectvs time Time Effect 0 1 0 Pharmacodynamics conc. vs effect 10 -3 Conc. (log) Effect

10 PK/PD - ICC - Manila, June 5th, 200510 Pharmacokinetic/ Pharmacodynamics in Drug Development and Evaluation The combination of in vitro modelling, proper design of animal model experiments, and the willingness to obtain sparse pharmacokinetic information on patients in clinical trials allows an in depth understanding of which aspects of drug exposure are most closely linked to therapeutic outcome as well as to toxicity. By providing such information to clinicians, drug therapy can achieve the goal of maximal therapeutic effect while engendering the lowest probability of encountering a drug exposure-related adverse event.

11 PK/PD - ICC - Manila, June 5th, 200511 Main PK/PD properties of antibiotics Available antibiotic can be divided in 3 groups time - dependent (T > MIC) AUC / MIC - dependent both AUC / MIC AND peak / MIC -dependent Caveat: this applies to the "clinically- meaningful" concentration window only …

12 PK/PD - ICC - Manila, June 5th, 200512 C min C max C min C max Clinically-meaningful concentration window … S. aureus; 24 h Barcia-Macay et al, submitted; Lemaire et al (2005) JAC ampicillin gentamicin All antibiotics are concentration- dependent, but it all dependent as how you look at them …

13 PK/PD - ICC - Manila, June 5th, 200513 Antibiotics Group # 1 (after W.A. Craig, 2000; revised 2003) 1. Antibiotics with time-dependent effects and no or little persistent effects PK/PD parameter Time above MIC Goal Maximize the exposure time AB  -lactams * 2d ISAP Educational Workshop, Stockholm, Sweden, 2000; revised accord. to Craig Craig, Infect. Dis. Clin. N. Amer., 17:479-502, 2003

14 PK/PD - ICC - Manila, June 5th, 200514 AB glycopeptides tetracyclines macrolides streptogramines fluconazole 2. Antibiotics with time-dependent effects, with little or no influence of the concentration BUT with persistent effects PK/PD parameter 24h AUC / MIC ratio Goal Optimize the quantity of AB administered Antibiotics Group # 2 (after W.A. Craig, 2000; revised 2003) * 2d ISAP Educational Workshop, Stockholm, Sweden, 2000; revised accord. to Craig Craig, Infect. Dis. Clin. N. Amer., 17:479-502, 2003

15 PK/PD - ICC - Manila, June 5th, 200515 AB aminoglycosides fluoroquinolones daptomycin 3. Antibiotics with concentration-dependent activity and with persistant effects (PAE) PK/PD parameter C max / MIC and 24h AUC / MIC ratios Goal Optimize both the peak and the quantity of drug Antibiotics Group # 3 (after W.A. Craig, 2000; revised 2003) * 2d ISAP Educational Workshop, Stockholm, Sweden, 2000; revised accord. to Craig Craig, Infect. Dis. Clin. N. Amer., 17:479-502, 2003

16 PK/PD - ICC - Manila, June 5th, 200516 PK / PD in action for the clinics Some achievements: once-daily dosing of aminoglycosides introduced in many countries amikacin, netilmicin (from bid to qd) isepamicin (registered essentially for qd dosing) 24h AUC / MIC and C max / MIC ratios used as guides for phase II / III trials, for treatment optimization and for registration of new antimicrobials moxifloxacin telithromycin dosage of beta-lactams adjusted to cover T > MIC in relation with the expected pathogen…

17 PK/PD - ICC - Manila, June 5th, 200517 PK/PD and resistance …

18 PK/PD - ICC - Manila, June 5th, 200518 0.010.101.0010.00 10 -2 1 concentration 10 -4 10 -6 10 -8 10 -10 MPC 10 = 9 Dong et al; AAC 43:1756-1758 Bactericidal effect of a FQ towards Mycobacterium bovis Mutant Prevention Concentration … MIC 99 = 0.8 "Classic" bactericidal effect Elimination of first mutants Surviving bacteria

19 PK/PD - ICC - Manila, June 5th, 200519 0.010.101.0010.00 10 -2 1 concentration 10 -4 10 -6 10 -8 10 -10 MPC 10 = 9 Dong et al; AAC 43:1756-1758 Mutant Prevention Concentration … MIC 99 = 0.8 Concentration which will inhibit the majority of the organisms Concentration necessary to prevent the selection of the first mutants Surviving bacteria

20 PK/PD - ICC - Manila, June 5th, 200520 "Window" where selection of mutants takes place … Time after administration MIC MPC concentration MSW concept from Drlica & Zhao, Rev. Med. Microbiol. 2004, 15:73-80 Mutation selection window

21 PK/PD - ICC - Manila, June 5th, 200521 "Window" where selection of mutants takes place … MIC MPC MSW No therapeutic effect Eradication of the first mutants Selection of the first mutants Time after administration concentration concept from Drlica & Zhao, Rev. Med. Microbiol. 2004, 15:73-80

22 PK/PD - ICC - Manila, June 5th, 200522 Therefore, new breakpoints for FQ … Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect. 2005 Apr;11(4):256-80. PMID: 15760423

23 PK/PD - ICC - Manila, June 5th, 200523 Or, correct assessment of telithromycin… 0 20 40 60 80 100 0.0150.030.060.120.250.512 Ery-S MIC (mg/L) % of strains PK/PD limit of sensitivity (0.25 mg/L) Ery-r But MIC 90 for Ery-r strains: 0.25-0.5... MIC 90 for Ery-s strains: < 0.06... Verhaegen & Verbist, Acta Clin. Belg. 2001, 56: 351

24 PK/PD - ICC - Manila, June 5th, 200524 PK/PD in 2005 … Use if for efficacy … Consider it for avoiding resistance

Download ppt "PK/PD - ICC - Manila, June 5th, 20051 The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul."

Similar presentations

MonteCarlo-Orlando06 - 1 Use of Monte Carlo simulations to select PK/PD breakpoints and therapeutic doses for antimicrobials in veterinary medicine PL.

MonteCarlo-Orlando Use of Monte Carlo simulations to select PK/PD breakpoints and therapeutic doses for antimicrobials in veterinary medicine PL.
Getting the Dose Right The View from Academia

Getting the Dose Right The View from Academia
Animal Model PK/PD: A Tool for Drug Development

Animal Model PK/PD: A Tool for Drug Development
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.

1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
Pharmacodynamics and the Dosing of Antibacterials

Pharmacodynamics and the Dosing of Antibacterials
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.

Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
Should we change the recommendations related to antibiotic drug dosage/drug duration? Workshop on Economic Epidemiology Makerere University August, 2009.

Should we change the recommendations related to antibiotic drug dosage/drug duration? Workshop on Economic Epidemiology Makerere University August, 2009.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.

Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.

Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Chapter 10: Restricting antibiotic use and optimizing dosing.

Chapter 10: Restricting antibiotic use and optimizing dosing.
Pharmacodynamics of Antibiotics

Pharmacodynamics of Antibiotics
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
25 MB of information … CONTENT OF THE CD-rom Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals.

25 MB of information … CONTENT OF THE CD-rom Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.

PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.

Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.

8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.

Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
EMEA London 2008 - 1 Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.

EMEA London Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.

Similar presentations

Ads by Google